EMA Says Yes To Janssen’s Talvey & 13 Other Drugs

Fourteen new products could be approved in the EU soon, after the European Medicines Agency gave them the thumbs up.

committee meeting
The EMA's human medicines committee held their latest monthly meeting this week • Source: Shutterstock

The European Medicines Agency has recommended that 14 new products be approved in the EU, including Talvey (talquetamab), Janssen’s treatment for relapsed and refractory multiple myeloma (RRMM), which is now set to become the first therapy targeting GPRC5D.*

Talvey is for use as monotherapy in adult patients with RRMM who have received at least three prior therapies, including...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography